课题基金 / 基金详情

项目摘要

项目成果

JULIA L HURWITZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The long term objective of this research is to produce an effective vaccine against respiratory syncytial virus (RSV), human parainfluenza virus-type 1 (hPIV-1) and human parainfluenza virus-type 3 (hPIV-3). Sendai virus (mouse PIV-1) has proven effective as a vaccine for hPIV-1 in non-human primate studies, and developments in reverse genetic engineering now permit additional genes to be inserted as passengers in the Sendal virus genome. The recombinant Sendal viruses (rSV) that incorporate passenger genes for membrane proteins of other respiratory viral pathogens may thus provide protective immunity both to hPIV-1 and to the other viruses. To provide a foundation for the confident formulation of vaccines to be tested in primates and humans, this section proposes an extensive course of experimentation to establish safety and efficacy in a laboratory rodent model, the cotton rat (Sigmodon hispidus), in which human respiratory viruses grow well after intranasal inoculation. Initial Specific Aims in this project involve testing and comparing individual strains of rSV that carry genes for the attachment and fusion proteins of RSV or hPIV-3. Experiments are designed to assess the vigor of the humoral and cellular immune responses generated by rSV inoculations, and to evaluate associated protective immunity and immunopathological reactions. Our last Aim is to test increasingly complex combinations of rSV strains, with the final objective of formulating an optimized rSV cocktail that will function safely and effectively to provide protection from RSV, hPIV-1 and hPIV-3. Studies proposed in this Project (Project 2) will be highly interactive with Projects 1 and 3. Products and concepts from Project 1 will support each of the Specific Aims, which will, in turn, support the non-human primate and clinical studies in Project 3. Ultimately, we propose that the research from this interactive Program Project will yield a safe, effective and affordable respiratory virus vaccine for children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV VACCINE RATIONALE
  • 批准号:
    8172940
  • 项目类别:
  • 资助金额:
    $8.41万
  • 财政年份:
    2010
  • 负责人:
    JULIA L HURWITZ
  • 依托单位:
HIV VACCINE RATIONALE
  • 批准号:
    7958598
  • 项目类别:
  • 资助金额:
    $5.81万
  • 财政年份:
    2009
  • 负责人:
    JULIA L HURWITZ
  • 依托单位:
HIV-envelope-specific CD4+ T-cell activation and functional potentials
HIV-envelope-specific CD4+ T-cell activation and functional potentials
海外基金